Gene · 3913
NIH grants2,633
NIH grants whose papers are about the gene, through NIH's grant-paper links.
221 to 240 of 2,633
Download this page as JSON| Grant | Title | LAMB2 papers | Newest fiscal year |
|---|---|---|---|
| R01AI022553 | Molecular Analysis of Host Immune Response in Leprosy | 1 | 2025 |
| R01AI124214 | Role of Type 2 Immunity in Innate Protection from C. difficile | 1 | 2025 |
| R01AI152477 | Mechanisms of Fecal Microbiota Transplant Protection from Recurrent C. difficile | 1 | 2025 |
| R01AR040312 | CD1-restricted T-cell Responses in Skin | 1 | 2025 |
| R01AR041836 | Function of Desmoglein 1/Pemphigus Foliaceus Antigen | 1 | 2025 |
| R01AR060364 | Molecular Pathways of Pain Generation in Osteoarthritis | 1 | 2025 |
| R01AR064251 | Osteoarthritis Progression And Sensory Pathway Alterations | 1 | 2025 |
| R01AR064327 | Reprogramming and Directed Differentiation of Skeletal Muscle Cells from hPSCs | 1 | 2025 |
| R01AR066530 | Regulators of epidermal growth and differentiation | 1 | 2025 |
| R01AR069297 | Regenerative Rehabilitation of Complex Musculoskeletal Injuries | 1 | 2025 |
| R01AR072009 | Investigations of the molecular genetics and pathogenesis of scoliosis. | 1 | 2025 |
| R01AR077019 | The Role of Mechanosensation Pathways in Osteoarthritis Joint Damage and Pain | 1 | 2025 |
| R01AR081640 | Hippo signaling as a critical regulator of lupus keratinocyte dysfunction | 1 | 2025 |
| R01CA142746 | Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines | 1 | 2025 |
| R01CA142779 | PD-1/PD-L1 modulation in cancer therapy | 1 | 2025 |
| R01CA163217 | Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma | 1 | 2025 |
| R01CA177875 | Targeting the vasculature to enhance anti-tumor immunity | 1 | 2025 |
| R01CA249087 | Tumor Organoid-Mediated Drug Testing and Clonality Analysis in Peritoneal Surface Disease of Intestinal Origin | 1 | 2025 |
| R01CA249424 | Regulation of extracellular vesicle biogenesis through cell adhesion | 1 | 2025 |
| R01CA249528 | Chemotherapy-driven evolution of the vascular secretome and its role in therapeutic resistance | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3913/grants?page=12